| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 3Small sample | 100.0% (3/3) | 66.7% (2/3) | +11.3% | +4.4% | -9.6% |
| 20D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +2.4% | +2.4% | +1.0% |
| 60D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -16.2% | -16.2% | -16.2% |
| 120D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +39.9% | +39.9% | +39.9% |
COMPANY RESEARCH
Newron Pharmaceuticals S.p.A.
NWRN.SW · Germany · Healthcare · Biotechnology
INSIDER SIGNAL
Insider activity score：60.4 / 100
2 insiders · 4 purchase events · €37k net purchases
Europe #292 · Germany #32
WHY THIS SIGNAL?
Score anatomy
Each bar shows the contribution to the current score; the weights and formula stay unchanged.
Cluster+21.0 / 35
How many distinct insiders bought in the cluster
Purchase size+17.0 / 25
Purchase value relative to company size and liquidity
Role+13.0 / 20
The seniority and relevance of participating insiders
Recency+5.4 / 10
How recently the purchases occurred
Conviction+10.0 / 10
How clearly buying stands out from other activity
What is holding the score back?
- ⚠ Buyer breadth is moderate · fewer than 4 distinct filers
- ⚠ Insider role contributes less on the current role scale
- ⚠ Purchase activity is becoming less recent
The role contribution uses the inverted role input of the current European model.
Buying concentration
100%
Largest buyer：Stefan Weber · 37k EUR
Gross qualified purchase transaction-line value：37k EUR
The headline € total is net buying for the screen; this module uses gross qualified purchase transaction-line values in the filing currency, so the amounts can differ. The current 15-day buyer-breadth input counts distinct buyers; value concentration is disclosed separately here.
This is a ranking under the current European screening rules—not a probability of gain, return forecast, or buy recommendation.
Key purchase quotes (filing currency)
| Filer | Price per unit | Trade date |
|---|---|---|
| Stefan Weber | 7.7 EUR | Oct 8, 2026 |
| Stefan Weber | 12.6 EUR | Aug 12, 2026 |
| Prisca Anand | — | Aug 11, 2026 |
Model details
Cluster breakdown (does not change the score)
- 15-day buyer breadth (count)
- 2 distinct reported filers
- Peak time window
- 2026-08-10 to 2026-08-12
- Current breadth input
- 0.600 (capped at 4+ buyers)
- Buyer independence
- Not yet measured; related-party fields are not cross-market comparable
What the filings show
- 🟢 Recent eligible purchase
Stefan Weber · 12k EUR · Price 7.7 EUR · Oct 8, 2026 - 🟢 PDMR purchase
Stefan Weber · 25k EUR · Price 12.6 EUR · Aug 12, 2026 - 🟢 PDMR purchase
Prisca Anand · 0 EUR · Price — · Aug 11, 2026 - 🟡 1 remaining qualified transaction line(s) across 1 disclosure(s)
Insider vs stock price
4 purchase day(s), 4 purchase line(s) in the 180-day window.
Daily close (CHF)Day with an insider purchase
Markers sit on the closing price of the transaction day. They show when insiders traded, not the price they paid or received. "Since" compares that day's close with the last close shown; it is what happened at this company, not a forecast.
If you had followed the purchase
Each row starts on the first close on or after the day a purchase was made public, the earliest a reader could have acted, and ends on the last close shown above.
| Made public | Insiders | In this stock, now | In the median peer stock, now | Difference |
|---|---|---|---|---|
| 2026-08-12 | 2 | 651 −34.9% | too few peers | — |
| 2026-10-08 | 1 | 1,137 +13.7% | too few peers | — |
Close to close, before costs, taxes, dividends and currency moves. The peer is the median of the other stocks on the same exchange for which this site holds prices (0 here), not an index. This is what happened, not a forecast: across all purchases on this site the typical gap is close to zero.
Insider timeline
2 insiders bought within 2 days, 11 Aug to 12 Aug: 2 Management board. 1 of them bought again later. The share closed at 12.59 on the first of those days and at 8.20 most recently (−34.9%). That week 164 companies across Europe disclosed insider purchases, an ordinary week (21 of the last 26).
Tap an item for what it means.
●A purchase: the bigger the dot, the more was bought
Each dot is one insider's purchases on one day. The dot's area follows the amount: the largest purchase here gets the largest dot. Hold the pointer over a dot to see the date and the amount. None of this company's filings in the window states an amount, so every dot is the same size.
▮Purple band: several insiders bought within 15 days
The band marks the stretch with the most different buyers: at most 15 days long and at least two people. Here it is 11 Aug – 12 Aug, with 2 insiders. Only the strongest stretch is marked. Several people deciding the same thing is harder to explain by one person's private reasons, but insiders often buy together just after a closed period ends, so compare it with the grey weekly bars.
Blue line: this share's price, −54.1% over these six months
The closing price of each day, from 17.87 on 2026-04-21 to 8.20 on 2026-10-16. The line has no scale; read it for high and low: a dot on a low stretch was bought cheaply, a dot on a high stretch was not.
Dashed line: the typical stock on the same exchange, +0.0%
Taken from the 89 other stocks on the same exchange that this site holds prices for. Each is measured from the first day of the window, and every day the middle one is drawn. It starts where the blue line starts, so the gap between the two is the difference: this share −54.1%, the typical one +0.0%, 54.1 points behind. It is not an index and not a comparison within one industry.
▂Grey bars: companies across Europe disclosing purchases each week
A taller bar is a week in which more companies disclosed insider purchases. The purple bar is the week of the band above: 164 companies, number 21 of the last 26 weeks. If that week was a peak anyway, buying together is less special than it looks.
This company: insiders buying per month, last 12 months
Nov
Dec
Jan
Feb
Mar
Apr
May
Jun
Jul
2Aug
Sep
1Oct
Darker bars are inside the 180-day window above.
Who traded
| Insider | Role | Purchases | Sales | Bought | First purchase | Share price since | Earlier purchases |
|---|---|---|---|---|---|---|---|
| Prisca Anand | Management board | 2 | — | — | 2026-08-10 | −35.6% | fewer than 5 completed |
| Stefan Weber | Management board | 2 | — | — | 2026-08-12 | −34.9% | fewer than 5 completed |
Why this score? · Model details
Priority = 100 × Σ(fixed weight × 0–1 rule-based input)
| Factor | Weight | This company input | Point contribution |
|---|---|---|---|
| 15-day buyer breadth (count) | 35% | 0.600 | 21.0 |
| Qualified-buy size | 25% | 0.681 | 17.0 |
| Role informativeness (inverted) | 20% | 0.350 | 7.0 |
| Recency | 10% | 0.536 | 5.4 |
| Buy/sell conviction | 10% | 1.000 | 10.0 |
This is a heuristic ordering under the current rules, not a calibrated return forecast. It explains why candidates rank differently; the public-filing evidence and data limits are shown below.
BULL VS BEAR
Two readings of this buying
The same filings, read two ways. Each line is a fact stored for this company with the number behind it, and appears only when that number crosses a fixed threshold. Neither side is a forecast and no winner is declared.
Since 2026-10-13: new on the bear side: loss-making. All bull and bear lists, and what followed each line in the past →
Where the evidence comes from
The two kinds of evidence disagree: the purchases themselves carry bull lines (more buyers than usual here, bought in the last two weeks), while share price and trading argue against (price down over six months, price trails its sector); company results argue against (loss-making). No data is held for: company actions.
- The insider purchases themselvesBullmore buyers than usual here, bought in the last two weeks Bearvalue concentrated in one buyer3 checked, under the threshold · 3 missing
- Share price and tradingBearprice down over six months, price trails its sector
- Short sellers1 checked, under the threshold
- Company resultsBearloss-making1 missing
- Company actionsno data held
Bull case · the buying is informative
- No insider bought in the 180 days before this window; 2 have bought in it. The buying is new for this company, not a habit.Record: after 3,134 earlier disclosures like this, the median 60-session excess return was −2.7%, within 1 percentage point of all comparable disclosures (−2.7%).
- The latest purchase is 9 days old (2026-10-08). The buying is current, not left over from an earlier quarter.
Bear case · discount it
- Stefan Weber accounts for 100% of the value bought. The other 1 buyer adds names more than money.Record: after 3,396 earlier disclosures like this, the median 60-session excess return was −3.4%, within 1 percentage point of all comparable disclosures (−3.5%).
- Company resultsThe company is loss-making on the latest captured figures: profit margin −284%.
- Share price and tradingThe share price is down 54% over six months (three months −33%, one month −29%). Insiders have bought into a fall the market has not reversed.Record (nearest stored case: price 20% or more below its prior 52-week high): after 11,077 earlier disclosures like this, the median 60-session excess return was −3.2%, within 1 percentage point of all comparable disclosures (−2.6%).
- Share price and tradingOver three months the share price changed −33% and the median of 271 Healthcare companies changed −6.3%: 27 points behind. The market has marked this company down against its own sector.
Evidence still missing
- No buyer here has 5 or more completed earlier purchases on record, so there is no track record to weigh.
- Only one reading of profitability is held (profit margin −284%). Whether earnings and cash flow are rising or falling needs the last two reports side by side.
- European notifications have no field saying whether a purchase was pre-arranged; there is no counterpart to the US 10b5-1 box. None of the 4 purchase lines mentions a plan, but a bare “Kauf” does not rule one out.
- The filings give the size of each trade, not what the buyer already held. Whether a purchase added 1% to a personal stake or doubled it is not known.
Checked and under the threshold: 4, 1 close to it
- BullAt most 2 insiders bought within any 15 days. Counted for the bull side from 3. close to the threshold
- EitherNet purchases equal 0.02% of the company's market value. Bull from 0.10%, bear below 0.01%.
- BearNo insider sale is recorded in the same 180 days.
- BearThe register of Bundesanzeiger shows no published net short position in this company. Positions under 0.5% are never published, so this does not show that nobody is short.
Both columns arrange stored facts only. They do not change the insider score or the ranking and are not investment advice.
Signal history
60.4 / 100
Latest recorded score
↑ +5.0 ptsversus the comparable snapshot on 2026-09-14 (34 calendar days apart)
- Recorded snapshots
- 33
- First snapshot
- 2026-08-28
Only scores captured when the scoring run completed are compared. These are raw signal scores saved when each full scoring run completed. They describe changes in research ranking, not price performance or returns.
Why did it change?
Decomposition across the five score factors between comparable snapshots; historical scores are not recalculated.
- Purchase size+0.6 pts
- Recency+4.3 pts
Signal score history
Fixed 0–100 scale; dates are spaced by calendar time.
Recent recorded points
- 57.7
- 55.9
- 54.8
- 54.6
- 60.4
View all recorded scores
| Snapshot date | Signal score |
|---|---|
| 2026-08-28 | 57.7 |
| 2026-08-31 | 57.1 |
| 2026-09-01 | 56.9 |
| 2026-09-02 | 56.8 |
| 2026-09-03 | 56.6 |
| 2026-09-04 | 56.5 |
| 2026-09-07 | 56.1 |
| 2026-09-08 | 56.0 |
| 2026-09-09 | 55.9 |
| 2026-09-10 | 55.8 |
| 2026-09-11 | 55.7 |
| 2026-09-14 | 55.4 |
| 2026-09-23 | 55.0 |
| 2026-09-24 | 54.9 |
| 2026-09-25 | 54.9 |
| 2026-09-28 | 54.8 |
| 2026-09-29 | 54.8 |
| 2026-09-30 | 54.8 |
| 2026-10-01 | 54.7 |
| 2026-10-02 | 54.7 |
| 2026-10-03 | 54.7 |
| 2026-10-04 | 54.7 |
| 2026-10-05 | 54.7 |
| 2026-10-06 | 54.6 |
| 2026-10-07 | 54.6 |
| 2026-10-08 | 65.0 |
| 2026-10-09 | 64.4 |
| 2026-10-12 | 62.6 |
| 2026-10-13 | 62.1 |
| 2026-10-14 | 61.6 |
| 2026-10-15 | 61.2 |
| 2026-10-16 | 60.8 |
| 2026-10-18 | 60.4 |
Sector context
- Buying breadth
- 6.1% (48 / 792 issuers)
- Sector rank
- #11 / 12
- 7D breadth change
- -0.4 pp · vs 2026-10-12 (6d)
- 30D breadth change
- History building
This is sector-level research context. It does not affect the Insider Signal or ranking.
Insider profile outcomes
Historical performance following insider filings. The company role is translated below each name while preserving the original title.
- Excess return = stock return − DAX return over the same period.
- Hit rate = completed events with positive excess return ÷ total completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
- Small-sample rule: n<5 is shown for transparency and is not scored.
Events are disclosure-level observations; related disclosures published on the same date may share a return path and may not be statistically independent. This research enrichment does not affect the insider score or ranking.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +11.5% | +11.5% | +11.5% |
| 20D | 2Small sample | 100.0% (2/2) | 100.0% (2/2) | +3.9% | +3.9% | +3.9% |
| 60D | 0No data | Awaiting maturity | — | — | — | — |
| 120D | 0No data | Awaiting maturity | — | — | — | — |
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +6.8% | +6.8% | +6.8% |
| 20D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -4.3% | -4.3% | -4.3% |
| 60D | 1Small sample | 100.0% (1/1) | 0.0% (0/1) | -11.6% | -11.6% | -11.6% |
| 120D | 1Small sample | 100.0% (1/1) | 100.0% (1/1) | +75.1% | +75.1% | +75.1% |
Market context
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- Volatility
- 61.5%
- Beta
- 0.85
- Avg daily volume
- CHF 586,570.6
VALUATION
- Market cap
- CHF 167.5M
- P/E
- —
FUNDAMENTALS
- Profit margin
- -283.6%
- ROE
- —
- Industry
- Biotechnology
Prices to 18 Oct 2026: OpenBB/yfinance. From OpenBB/yfinance, captured 15 Oct 2026: Market cap, Profit margin, Beta, Industry. It does not affect the insider score or rank.
Disclosed net short positions
The Bundesanzeiger register, read 18 Oct 2026, publishes no net short position of 0.5% or more in this issuer. Positions below 0.5% are never published, so this is not evidence that nobody is short.
Short-position disclosures are external context; they do not affect the insider score, ranking, or filing eligibility.
Insiders' buying price vs the latest close
No purchase price could be compared with the share price (price or share count missing, another currency, or far from that day's close).
Buying size vs market trading
Quote currency is not verified.
Market-data coverage: 259 verified sessions · Latest session: 2026-10-16 · Ratio status: Unavailable
Recent and largest purchase events / preceding 60-session ADTV
- Oct 08 · Stefan Weber · Vorstand b) Erstmeldung11,550 EUR · —Quote currency is not verified.
- Aug 12 · Stefan Weber · Vorstand b) Erstmeldung25,203 EUR · 4.42%569,689 EUR ADTV
- Aug 11 · Prisca Anand · Vorstand b) Erstmeldung— · —Some purchases lack a valid value; aggregate ratio withheld.
- Aug 10 · Prisca Anand · Vorstand b) Erstmeldung— · —Some purchases lack a valid value; aggregate ratio withheld.
Traded value is estimated as close × shares traded, in major currency units. Includes disclosed qualifying purchases; disclosures may lag. Contractual or planned acquisitions are not necessarily discretionary. Ratios describe relative trading size, not market participation or score contributions.
Latest news
No news has been captured for this company.
Regulatory filings
- Insider filing announcement · published 2026-10-08 · trade date 2026-10-08
- Insider filing announcement · published 2026-08-12 · trade date 2026-08-12
- Insider filing announcement · published 2026-08-12 · trade date 2026-08-11
Unfold all 6 filings
- Insider filing announcement · published 2026-10-08 · trade date 2026-10-08
- Insider filing announcement · published 2026-08-12 · trade date 2026-08-12
- Insider filing announcement · published 2026-08-12 · trade date 2026-08-11
- Insider filing announcement · published 2026-08-12 · trade date 2026-08-10
- Insider filing announcement · published 2025-12-03 · trade date 2025-12-02
- Insider filing announcement · published 2025-11-27 · trade date 2025-11-26
Filing evidence
These are underlying national-feed records from the 365-day window ending on the saved ranking snapshot. The score uses only the latest 180 days; older qualifying equity purchases remain visible for audit but do not enter the current score. The original filer, role, transaction classification, instrument, price, volume, value and source fields are retained. The first three rows are shown; remaining records can be unfolded for audit. Other transaction types are retained but excluded from the score.
Excluded transactions & classification
4 qualifying purchase disclosure(s) · 4 transaction line(s)
Oct 8, 2026Kauf
Stefan Weber · Vorstand b) Erstmeldung
Aktie · 1500 shares × 7,70 EUR · 11.550,00 EUR
Open filingAug 12, 2026Kauf
Stefan Weber · Vorstand b) Erstmeldung
Aktie · 2000.2381 shares × 12,60 EUR · 25.203,00 EUR
Open filingAug 11, 2026Kauf
Prisca Anand · Vorstand b) Erstmeldung
Aktie · — shares × — · —
Open filingUnfold all 1 remaining filing row(s)
| Transaction date | Published | Filer | Role | Transaction | Instrument | Price (local currency) | Quote currency | Volume | Reported value (local currency) | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | 2026-08-12 | Prisca Anand | Vorstand b) Erstmeldung | Kauf | Aktie | — | EUR | — | — | Open filing |
Showing 4 of 4 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Other disclosed transactions · excluded from score
View 2 other transaction(s)
Dec 2, 2025Verkauf Geschäft i.R. eines Mitarbeiterbeteiligungsprogramms
Luca Benatti · Aufsichtsrat b) Erstmeldung
Aktie · — shares × — · —
Open filingNov 26, 2025Verkauf Geschäft i.R. eines Mitarbeiterbeteiligungsprogramms
Luca Benatti · Aufsichtsrat b) Erstmeldung
Aktie · — shares × — · —
Open filingShowing 2 of 2 matching raw-feed row(s) from the current 365-day research window. Prices and reported values remain in the filing currency and its major unit (for example, UK pence are parsed as GBP). The screen-level € aggregate is separately FX-normalised for research ranking, not a trade-date conversion.
Snapshot & identity
- Snapshot date
- 2026-10-18
- Ticker
- NWRN.SW
- ISIN
- IT0004147952
- Sector
- Healthcare
- Industry
- Biotechnology
Company logos by Parqet